US6716432B1
(en)
*
|
1988-12-16 |
2004-04-06 |
James Cleland Paton |
Pneumolysin mutants and pneumococcal vaccines made therefrom
|
CA2059693C
(en)
*
|
1991-01-28 |
2003-08-19 |
Peter J. Kniskern |
Polysaccharide antigens from streptococcus pneumoniae
|
US5391712A
(en)
*
|
1991-08-30 |
1995-02-21 |
Beckman Instruments, Inc. |
Non-hemolytic streptolysin O variants
|
US5928900A
(en)
*
|
1993-09-01 |
1999-07-27 |
The Rockefeller University |
Bacterial exported proteins and acellular vaccines based thereon
|
WO1995016711A1
(es)
*
|
1993-12-17 |
1995-06-22 |
Universidad De Oviedo |
Anticuerpos contra la neumolisina y sus aplicaciones
|
US8791237B2
(en)
|
1994-11-08 |
2014-07-29 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of non-hodgkins lymphoma
|
HUP0002475A3
(en)
*
|
1997-07-21 |
2002-01-28 |
Baxter Healthcare S A Wallisel |
Modified immunogenic pneumolysin compositions as vaccines
|
HU228499B1
(en)
*
|
1999-03-19 |
2013-03-28 |
Smithkline Beecham Biolog |
Streptococcus vaccine
|
GB9906437D0
(en)
*
|
1999-03-19 |
1999-05-12 |
Smithkline Beecham Biolog |
Vaccine
|
GB9918319D0
(en)
|
1999-08-03 |
1999-10-06 |
Smithkline Beecham Biolog |
Vaccine composition
|
GB0022742D0
(en)
*
|
2000-09-15 |
2000-11-01 |
Smithkline Beecham Biolog |
Vaccine
|
AU1412702A
(en)
|
2000-10-27 |
2002-05-06 |
Chiron Spa |
Nucleic acids and proteins from streptococcus groups a and b
|
GB0109297D0
(en)
|
2001-04-12 |
2001-05-30 |
Glaxosmithkline Biolog Sa |
Vaccine
|
PT2255826E
(pt)
|
2002-08-02 |
2016-06-08 |
Glaxosmithkline Biologicals Sa |
Composições de vacina de neisseria compreendendo uma combinação de antigénios
|
AU2003278166B2
(en)
|
2002-11-01 |
2009-01-29 |
Glaxosmithkline Biologicals S.A. |
Immunogenic composition
|
ES2451620T3
(es)
*
|
2002-11-07 |
2014-03-28 |
Synergy America, Inc. |
Composiciones y métodos destinados a tratar o prevenir la infección neumocócica
|
AU2004219910B2
(en)
|
2003-03-13 |
2010-06-17 |
Glaxosmithkline Biologicals S.A. |
Purification process for bacterial cytolysin
|
PT1648500E
(pt)
|
2003-07-31 |
2014-10-10 |
Novartis Vaccines & Diagnostic |
Composições imunogénicas para estreptococos piogenes
|
US8945589B2
(en)
|
2003-09-15 |
2015-02-03 |
Novartis Vaccines And Diagnostics, Srl |
Immunogenic compositions for Streptococcus agalactiae
|
US8574596B2
(en)
|
2003-10-02 |
2013-11-05 |
Glaxosmithkline Biologicals, S.A. |
Pertussis antigens and use thereof in vaccination
|
US20060257421A1
(en)
*
|
2004-02-13 |
2006-11-16 |
Martina Ochs |
Pneumolysin derivatives
|
WO2005108419A1
(en)
*
|
2004-05-07 |
2005-11-17 |
Lea-Ann Kirkham |
Mutant cholesterol-binding cytolysin proteins
|
GB0410220D0
(en)
*
|
2004-05-07 |
2004-06-09 |
Kirkham Lea Ann |
Mutant pneumolysin proteins
|
EP2612679A1
(en)
|
2004-07-29 |
2013-07-10 |
Novartis Vaccines and Diagnostics, Inc. |
Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
|
GB0421083D0
(en)
*
|
2004-09-22 |
2004-10-27 |
Glaxosmithkline Biolog Sa |
Purification process
|
JP2008544949A
(ja)
|
2004-10-08 |
2008-12-11 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
化膿性レンサ球菌のための免疫激性組成物および治療用組成物
|
GB0505996D0
(en)
|
2005-03-23 |
2005-04-27 |
Glaxosmithkline Biolog Sa |
Fermentation process
|
TWI457133B
(zh)
|
2005-12-13 |
2014-10-21 |
Glaxosmithkline Biolog Sa |
新穎組合物
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
AR058707A1
(es)
|
2005-12-22 |
2008-02-20 |
Glaxosmithkline Biolog Sa |
Vacuna, procedimiento para fabricarla y su uso
|
CA2636566C
(en)
|
2006-01-17 |
2018-03-13 |
Arne Forsgren |
A novel surface exposed haemophilus influenzae protein (protein e; pe)
|
US20090181078A1
(en)
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
US8273361B2
(en)
|
2006-09-26 |
2012-09-25 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
PL2086582T3
(pl)
|
2006-10-12 |
2013-04-30 |
Glaxosmithkline Biologicals Sa |
Kompozycja zawierająca adiuwant w postaci emulsji typu olej w wodzie
|
PT2086582E
(pt)
|
2006-10-12 |
2013-01-25 |
Glaxosmithkline Biolog Sa |
Vacina compreendendo uma emulsão adjuvante óleo em água
|
US9717788B2
(en)
|
2007-03-02 |
2017-08-01 |
Glaxosmithkline Biologicals Sa |
Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
|
CN105106971A
(zh)
|
2007-03-02 |
2015-12-02 |
葛兰素史密丝克莱恩生物有限公司 |
疫苗组合物及其在刺激免疫反应中的用途
|
EP2386567B1
(en)
*
|
2007-04-13 |
2014-10-29 |
The Board Of Regents Of The University Of Oklahoma |
Mutants of cholesterol-dependent cytolysins and uses thereof
|
EP2167121B1
(en)
|
2007-06-26 |
2015-09-02 |
GlaxoSmithKline Biologicals S.A. |
Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
RU2471497C2
(ru)
|
2007-09-12 |
2013-01-10 |
Новартис Аг |
Мутантные антигены gas57 и антитела против gas57
|
CN101977926B
(zh)
|
2007-12-21 |
2014-10-08 |
诺华股份有限公司 |
链球菌溶血素o的突变形式
|
EA201001479A1
(ru)
|
2008-04-16 |
2011-06-30 |
Глаксосмитклайн Байолоджикалс С.А. |
Вакцина
|
GB0815872D0
(en)
|
2008-09-01 |
2008-10-08 |
Pasteur Institut |
Novel method and compositions
|
US8758766B2
(en)
*
|
2008-12-24 |
2014-06-24 |
The Kingdom of The Netherlands, Represented by The Mininster of Health, Welfare and Sport, on Behalf of The Minster The National Institute of Public Health and The Environment |
Modified Streptococcus pneumoniae pneumolysin (PLY) polypeptides
|
AU2010227220B2
(en)
|
2009-03-24 |
2014-11-13 |
Glaxosmithkline Biologicals S.A. |
Combinations of meningococcal factor H binding protein and pneumococcal saccharide conjugates
|
TWI494125B
(zh)
|
2009-06-05 |
2015-08-01 |
Infectious Disease Res Inst |
合成的葡萄吡喃糖基脂質佐劑
|
US20120237536A1
(en)
|
2009-09-10 |
2012-09-20 |
Novartis |
Combination vaccines against respiratory tract diseases
|
EP2515938A4
(en)
*
|
2009-12-22 |
2013-08-28 |
Sanofi Pasteur Ltd |
IMMUNOGENIC COMPOSITIONS
|
CN102939105B
(zh)
|
2009-12-22 |
2016-11-16 |
赛诺菲巴斯德有限公司 |
免疫原性组合物和相关的方法
|
DK2544693T3
(da)
|
2010-03-09 |
2017-12-04 |
Biomedical Res Models Inc |
Hidtil ukendt tilgang til vaccination gennem slimhinder mod herpes simplex-virus type-2
|
GB201003924D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
JP2013521326A
(ja)
|
2010-03-10 |
2013-06-10 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
免疫原性組成物
|
WO2011130434A2
(en)
|
2010-04-13 |
2011-10-20 |
Celldex Therapeutics Inc. |
Antibodies that bind human cd27 and uses thereof
|
GB201015132D0
(en)
|
2010-09-10 |
2010-10-27 |
Univ Bristol |
Vaccine composition
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
GB201022007D0
(en)
|
2010-12-24 |
2011-02-02 |
Imp Innovations Ltd |
DNA-sensor
|
US9181308B2
(en)
|
2011-03-28 |
2015-11-10 |
St. Jude Children's Research Hospital |
Methods and compositions employing immunogenic fusion proteins
|
US9044420B2
(en)
|
2011-04-08 |
2015-06-02 |
Immune Design Corp. |
Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
|
UY34073A
(es)
|
2011-05-17 |
2013-01-03 |
Glaxosmithkline Biolog Sa |
Vacuna mejorada de streptococcus pneumoniae y métodos de preparación.
|
CN104363892A
(zh)
|
2012-02-07 |
2015-02-18 |
传染性疾病研究院 |
包含tlr4激动剂的改进佐剂制剂及其使用方法
|
WO2013131983A1
(en)
|
2012-03-07 |
2013-09-12 |
Novartis Ag |
Adjuvanted formulations of streptococcus pneumoniae antigens
|
EP3388835B1
(en)
|
2012-05-16 |
2020-04-01 |
Immune Design Corp. |
Vaccines for hsv-2
|
US9566325B2
(en)
|
2013-01-07 |
2017-02-14 |
Biomedical Research Models, Inc. |
Therapeutic vaccines for treating herpes simplex virus type-2 infections
|
EP2964665B1
(en)
|
2013-03-08 |
2018-08-01 |
Pfizer Inc |
Immunogenic fusion polypeptides
|
SG11201508092YA
(en)
|
2013-04-18 |
2015-10-29 |
Immune Design Corp |
Gla monotherapy for use in cancer treatment
|
US11207396B2
(en)
|
2013-05-17 |
2021-12-28 |
The Board Of Regents Of The University Of Texas System |
Immunization to protect against adverse cardiac events relating to pneumococcal infection
|
US9463198B2
(en)
|
2013-06-04 |
2016-10-11 |
Infectious Disease Research Institute |
Compositions and methods for reducing or preventing metastasis
|
KR20220100041A
(ko)
|
2013-12-31 |
2022-07-14 |
인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) |
단일 바이알 백신 제형
|
US9815886B2
(en)
|
2014-10-28 |
2017-11-14 |
Adma Biologics, Inc. |
Compositions and methods for the treatment of immunodeficiency
|
US10562941B2
(en)
|
2014-11-21 |
2020-02-18 |
The Board Of Regents Of The University Of Oklahoma |
Pneumolysin mutants and methods of use thereof
|
WO2016145085A2
(en)
|
2015-03-09 |
2016-09-15 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
GB201518684D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Vaccine
|
WO2017176076A1
(en)
|
2016-04-06 |
2017-10-12 |
Ewha University - Industry Collaboration Foundation |
A peptide with ability to penetrate cell membrane
|
JP7038064B2
(ja)
|
2016-04-18 |
2022-03-17 |
セルデックス セラピューティクス インコーポレイテッド |
ヒトcd40に結合するアゴニスト抗体およびその使用
|
KR102483033B1
(ko)
|
2016-05-16 |
2022-12-30 |
액세스 투 어드밴스드 헬스 인스티튜트 |
페길화된 리포솜 및 이의 용도
|
EP4112638A1
(en)
|
2016-05-16 |
2023-01-04 |
Access to Advanced Health Institute |
Formulation containing tlr agonist and methods of use
|
WO2017210364A1
(en)
|
2016-06-01 |
2017-12-07 |
Infectious Disease Research Institute |
Nanoalum particles containing a sizing agent
|
GB201610599D0
(en)
|
2016-06-17 |
2016-08-03 |
Glaxosmithkline Biologicals Sa |
Immunogenic Composition
|
US10259865B2
(en)
|
2017-03-15 |
2019-04-16 |
Adma Biologics, Inc. |
Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
|
CA3067224A1
(en)
|
2017-06-15 |
2018-12-20 |
Infectious Disease Research Institute |
Nanostructured lipid carriers and stable emulsions and uses thereof
|
CN111315406A
(zh)
|
2017-09-08 |
2020-06-19 |
传染病研究所 |
包括皂苷的脂质体调配物及其使用方法
|
KR20210011919A
(ko)
|
2018-04-17 |
2021-02-02 |
셀덱스 쎄라퓨틱스, 인크. |
항-cd27 항체 및 항-pd-l1 항체 및 이중특이적 작제물
|
US20220016168A1
(en)
|
2018-12-11 |
2022-01-20 |
Celldex Therapeutics, Inc. |
Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
|
US20220054632A1
(en)
|
2018-12-12 |
2022-02-24 |
Glaxosmithkline Biologicals Sa |
Modified carrier proteins for o-linked glycosylation
|
BR112021023726A2
(pt)
|
2019-05-25 |
2022-02-15 |
Infectious Disease Res Inst |
Composição e método para secagem por pulverização de uma emulsão de vacina adjuvante
|
EP3900739A1
(en)
|
2020-04-21 |
2021-10-27 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein
|
EP3919076A1
(en)
|
2020-06-02 |
2021-12-08 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Synthetic oligosaccharide vaccines against streptococcus pneumoniae with microparticle adjuvant formulations
|
AU2021337493A1
(en)
|
2020-09-04 |
2023-05-18 |
Access To Advanced Health Institute |
Co-lyophilized rna and nanostructured lipid carrier
|
KR20240006541A
(ko)
|
2021-04-09 |
2024-01-15 |
셀덱스 쎄라퓨틱스, 인크. |
Ilt4에 대한 항체, 이중특이적 항-ilt4/pd-l1 항체 및 이의 용도
|
WO2023077521A1
(en)
|
2021-11-08 |
2023-05-11 |
Celldex Therapeutics, Inc |
Anti-ilt4 and anti-pd-1 bispecific constructs
|
CA3237496A1
(en)
|
2021-11-18 |
2023-05-25 |
Matrivax, Inc. |
Immunogenic fusion protein compositions and methods of use thereof
|
WO2024052882A1
(en)
|
2022-09-09 |
2024-03-14 |
Access To Advanced Health Institute |
Immunogenic vaccine composition incorporating a saponin
|